The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study
    Russo, Francesco
    Linsalata, Michele
    Clemente, Caterina
    D'Attoma, Benedetta
    Orlando, Antonella
    Campanella, Giovanna
    Giotta, Francesco
    Riezzo, Giuseppe
    BMC CANCER, 2013, 13
  • [2] 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE (FEC COMBINATION) IN ADVANCED BREAST-CANCER
    ZAMAGNI, C
    MARTONI, A
    ERCOLINO, L
    BARONI, M
    TANNEBERGER, S
    PANNUTI, F
    JOURNAL OF CHEMOTHERAPY, 1991, 3 (02) : 126 - 129
  • [3] Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy
    Kailajärvi, MEH
    Salminen, EK
    Paija, OMM
    Virtanen, AM
    Leino, AE
    Irjala, KA
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1271 - 1274
  • [4] Clinical Comparison on the Safety and Efficacy of Fluorouracil/Pirarubicin/Cyclophosphamide (FPC) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as Postoperative Adjuvant Chemotherapy in Breast Cancer
    Li, Ying
    Tang, Jin-Hai
    Huang, Xin-En
    Li, Chen-guang
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (07) : 1795 - 1798
  • [5] 5-FLUOROURACIL, ADRIAMYCIN, CYCLOPHOSPHAMIDE (FAC) VS 5-FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE (FEC) IN METASTATIC BREAST-CANCER
    LOPEZ, M
    PAPALDO, P
    DILAURO, L
    VICI, P
    CARPANO, S
    CONTI, EMS
    ONCOLOGY, 1989, 46 (01) : 1 - 5
  • [6] Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
    Kluger, N.
    Jacot, W.
    Frouin, E.
    Rigau, V.
    Poujol, S.
    Dereure, O.
    Guillot, B.
    Romieu, G.
    Bessis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2879 - 2884
  • [7] Gut Peptide Profile and Chemotherapy-associated Dyspepsia Syndrome in Patients with Breast Cancer Undergoing FEC60 Chemotherapy
    Riezzo, Giuseppe
    Clemente, Caterina
    Linsalata, Michele
    D'Attoma, Benedetta
    Orlando, Antonella
    Campanella, Giovanna
    Giotta, Francesco
    Russo, Francesco
    ANTICANCER RESEARCH, 2013, 33 (11) : 4951 - 4957
  • [8] Toxicity data of a multicenter, randomized study of standard FEC (FEC60) vs FEC with double epirubicin (EPI) (FEC120) plus G-CSF in metastatic breast cancer (MBC)
    Riccardi, A
    Brugnatelli, S
    Giordano, M
    Danova, M
    Tinelli, C
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 697 - 697
  • [9] FAC (FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE) AS 2ND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER PROGRESSING UNDER FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) CHEMOTHERAPY
    CATIMEL, G
    CHAUVIN, F
    GUASTALLA, JP
    REBATTU, P
    BIRON, P
    CLAVEL, M
    ANNALS OF ONCOLOGY, 1994, 5 (01) : 95 - 97
  • [10] Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer
    Marty, ME
    Coombes, RC
    Peckitt, C
    López, FRP
    Tres, A
    Morvan, F
    Tubiana-Mathieu, N
    Espié, M
    Bliss, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 25S - 25S
12345